Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Bio-Path Holdings reports positive Q1 results and advances key drug programs

Bio-Path Holdings (BPTH) showcased progress in key drug programs, financial stability, and global patent expansion. While facing regulatory and competitive challenges, the company is well-positioned to capitalize on opportunities in the biopharmaceutical sector. Optimism for future growth and innovation was expressed by CEO Peter Nielsen during the earnings call.

Bio-Path reports Q2 progress with prexigebersen and promising trials

Bio-Path Holdings showcased progress in clinical trials and financial management, emphasizing innovation and commitment to revolutionize cancer treatment.
While facing challenges in commercialization and market competition, the company's strong dedication to personalized medicine and promising trial results present growth opportunities.
With a focus on leveraging molecular biomarkers and advancing pipeline candidates, Bio-Path is strategically positioned to drive future success in the oncology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Shares of Bio-Path Holdings BPTH, -0.06% fell late Thursday after the company said it had reached a deal for an at-the-market share offering.

Bio-Path Holdings shares sink 6% after deal for at-the-market offering

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. “The new year is off to a strong start as we build off positive data generated in 2023 that compel us to advance these studies as quickly as possible and to file for regulatory designations that could accelerate our path to approval,” said Peter H.

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q4 2023. To view the full announcement, including downloadable images, bios, and more, click here.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23

Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today's event is being recorded.

Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript

HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2023 and provided an update on recent corporate developments. “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Bio-Path Holdings Reports Full Year 2023 Financial Results

HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024 Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells' Ability to Produce Bcl-2 Protein BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells' Ability to Produce Bcl-2 Protein

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call.

Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript

HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. “The third quarter marked a particularly progressive time at Bio-Path as we reported compelling clinical data from our Phase 2 trial of prexigebersen in acute myeloid leukemia (AML),” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Bio-Path Holdings Reports Third Quarter 2023 Financial Results

HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.

Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference

Dallas, Texas--(Newsfile Corp. - August 30, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2023. The full report can be accessed by clicking on the following link: BPTH Q2 23 Report To view the full announcement, including downloadable images, bios, and more, click here.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call.

Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript

HOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2023 and provided an update on recent corporate developments. "Our clinical progress this quarter was highlighted by the compelling interim results from Stage 2 of our Phase 2 study of prexigebersen as a treatment for acute myeloid leukemia, a blood cancer for which there are limited treatment options and for which the prognosis is grave," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Bio-Path Holdings Reports Second Quarter 2023 Financial Results

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 15, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023 and to provide a business overview.

Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023

HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of a public offering of 3,500,000 shares of common stock, together with accompanying common stock purchase warrants, at a price to the public of $0.60 per share and accompanying common stock purchase warrant, for aggregate gross proceeds to the Company of approximately $2.1 million, before deducting the fees and estimated offering expenses payable by the Company. Each share of common stock is being sold in the offering together with a common stock purchase warrant to purchase one share of common stock at an exercise price of $0.60 per share. The common stock purchase warrants are exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about August 7, 2023, subject to customary closing conditions.

Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering

Interim Data Analysis Demonstrates Significant Clinical Improvement and Tolerable Safety Profile in High-Risk Patients

Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer Advancing to Second Cohort of Phase 1/1b Clinical Trial Evaluating BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer

Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.

Why Is Bio-Path (BPTH) Stock Down 12% Today?

Dallas, Texas--(Newsfile Corp. - June 2, 2023) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: BPTH Q1 23 Report To view the full announcement, including downloadable images, bios, and more, click here.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23

Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call.

Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript

HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent corporate developments. “We continue to make important progress advancing our clinical programs as we await topline results from several key cohorts in our Phase 1/1b study of BP1001-A in solid tumors, Phase 1/1b study of BP1002 in relapsed/refractory AML, and Phase 2 study of prexigebersen in AML,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

News for Bio-Path Holdings Stock (BPTH)